Patents Assigned to Quest Diagnostics Investments LLC
-
Patent number: 10494629Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: GrantFiled: August 31, 2018Date of Patent: December 3, 2019Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Publication number: 20190330704Abstract: The present technology provides polynucleotide compositions and methods of using the same to detect circulating tumor DNA (ctDNA) in a patient. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: December 27, 2017Publication date: October 31, 2019Applicant: Quest Diagnostics Investments LLCInventors: Suzzette Arnal, Taraneh Angeloni
-
Publication number: 20190302095Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric technique.Type: ApplicationFiled: June 17, 2019Publication date: October 3, 2019Applicant: Quest Diagnostics Investments LLCInventors: Stephen W. TAYLOR, Michael McPHAUL, Richard E. REITZ, Zhaohui CHEN, Nigel CLARKE
-
Publication number: 20190285654Abstract: Provided herein are methods for high throughput quantitation of testosterone utilizing at least two different derivatizing agents of different masses. In another aspect, provided herein are methods for determining the amount of testosterone in each of a plurality of human samples with a single mass spectrometric assay by subjecting each of a plurality of human samples to a different derivatizing agent to generate a differently derivatized testosterone in each of the plurality of samples; combining the plurality of samples to form a multiplex sample; and quantifying the amount of testosterone in each sample by mass spectrometry.Type: ApplicationFiled: March 15, 2019Publication date: September 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Mildred M. Goldman, Scott Goldman, Juliet Coletti, Nigel Clarke
-
Publication number: 20190284639Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient exhibiting cancer symptoms, or at risk for hereditary cancers such as breast cancer, ovarian cancer, colon cancer, or skin cancer, will benefit from treatment with one or more therapeutic agents. These methods are based on detecting hereditary cancer-related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device (e.g., MITRA Tip). Kits for use in practicing the methods are also provided.Type: ApplicationFiled: November 13, 2017Publication date: September 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Nigel J. Clarke
-
Publication number: 20190285594Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.Type: ApplicationFiled: March 15, 2019Publication date: September 19, 2019Applicant: Quest Diagnostics Investments LLCInventors: Darren Weber, Michael Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
-
Publication number: 20190276904Abstract: The present disclosure provides rapid and non-invasive methods for determining whether a patient will benefit from treatment with therapeutic agents that inhibit Hepatitis C virus (HCV). These methods are based on detecting HCV RNA and/or anti-HCV antibodies in small-volume dried biological fluid samples that are collected using a microsampling device. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: November 13, 2017Publication date: September 12, 2019Applicant: Quest Diagnostics Investments LLCInventors: Amy Rogers, John Leake, Nigel J. Clarke, Russell E. Baumann
-
Publication number: 20190211408Abstract: The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: June 2, 2017Publication date: July 11, 2019Applicant: Quest Diagnostics Investments LLCInventors: Peter Lee, Raymond Huang, Kristin Ramos, Jules Chen, Michelle Tabb
-
Publication number: 20190206666Abstract: Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.Type: ApplicationFiled: July 31, 2018Publication date: July 4, 2019Applicant: Quest Diagnostics Investments LLCInventors: Darren Weber, Nigel Clarke
-
Patent number: 10324082Abstract: Methods are described for determining the amount of insulin in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. Also provided herein are mass spectrometric methods for detecting and quantifying insulin and b-chain in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.Type: GrantFiled: March 2, 2016Date of Patent: June 18, 2019Assignee: Quest Diagnostics Investments LLCInventors: Stephen W. Taylor, Michael McPhaul, Richard E. Reitz, Zhaohui Chen, Nigel Clarke
-
Publication number: 20190177801Abstract: Described herein are methods for diagnosing melanoma or basal cell carcinoma based on mutations in the DDR2 gene. Further, a distinct subgroup of BRAF-mutated melanomas have somatic mutations in the DDR2 gene as well. Applications of this finding to routine diagnostics include the molecular stratification of melanoma, and the tissue identification of targetable DDR2 kinase mutations in routine formalin-fixed paraffin-embedded sections. Described herein are methods, compositions and kits related to the discovery that DDR2 mutations may be markers for melanoma generally, and BRAF-mediated melanoma in particular, opening up the possibility of dual therapy for melanoma by targeting both DDR2 and BRAF.Type: ApplicationFiled: December 17, 2018Publication date: June 13, 2019Applicant: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Daniel M. Jones, Yongbao Wang, Shere Billouin-Frazier, Justin Windham
-
Publication number: 20190177797Abstract: The present invention relates to methods for amplifying various regions of the cystic fibrosis transmembrane regulator (CFTR) gene. Methods are provided for amplifying one or all 27 exons of the CFTR gene and a portion of the CFTR promoter region in a single tube. The method can identify the presence or absence of CF deletions or insertions in a sample and assist in the diagnosis of a genetic predisposition to cystic fibrosis.Type: ApplicationFiled: December 17, 2018Publication date: June 13, 2019Applicant: Quest Diagnostics Investments LLCInventors: Feras Hantash, Weimin Sun
-
Publication number: 20190177805Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter āCā region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.Type: ApplicationFiled: August 9, 2017Publication date: June 13, 2019Applicant: Quest Diagnostics Investments LLCInventors: Kevin Qu, Feras Hantash, Amber Donahue
-
Patent number: 10316372Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.Type: GrantFiled: September 7, 2018Date of Patent: June 11, 2019Assignee: QUEST DIAGNOSTICS INVESTMENTS LLCInventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
-
Publication number: 20190170711Abstract: Provided are methods for detecting or determining the amount of guanidinoacetate (GAA), creatine, and creatinine by mass spectrometry.Type: ApplicationFiled: August 6, 2018Publication date: June 6, 2019Applicant: Quest Diagnostics Investments LLCInventor: Thomas C. Lynn
-
Publication number: 20190112657Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.Type: ApplicationFiled: October 26, 2018Publication date: April 18, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
-
Publication number: 20190112653Abstract: The present technology relates to methods for determining whether a patient having thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, e.g., lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to a specific set of thyroid cancer-related genes. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: December 30, 2016Publication date: April 18, 2019Applicant: Quest Diagnostics Investments LLCInventors: Shih-Min CHENG, Joseph J. CATANESE, Andrew GRUPE, Feras HANTASH, Frederic M. WALDMAN, Kevin QU
-
Publication number: 20190112662Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.Type: ApplicationFiled: October 5, 2018Publication date: April 18, 2019Applicant: Quest Diagnostics Investments LLCInventors: Maher Albitar, Wanlong Ma
-
Publication number: 20190107536Abstract: Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.Type: ApplicationFiled: December 4, 2018Publication date: April 11, 2019Applicant: I Quest Diagnostics Investments LLCInventors: Stanley J. Naides, Joanna Popov
-
Publication number: 20190100808Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: ApplicationFiled: October 19, 2018Publication date: April 4, 2019Applicant: Quest Diagnostics Investments LLCInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender